Ad is loading...
MENU

LTRN Stock Lantern Pharma (LTRN, $3.08) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 19, 2024

A.I.dvisor
at Tickeron.com
Loading...
LTRN - Lantern Pharma
MACD signal
Bearish Trend
Odds of DOWN Trend
Tickeron
MACD signal
Price: $3.08
Daily change: -$0.08 (-2.53%)
Daily volume: 47.9K
Industry: Biotechnology
This is a Bearish indicator signaling LTRN's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 48 similar cases where LTRN's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:

LTRN in downward trend: price may decline as a result of having broken its higher Bollinger Band on November 08, 2024

LTRN broke above its upper Bollinger Band on November 08, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 31 similar instances where the stock broke above the upper band. In of the 31 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on LTRN as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LTRN turned negative on November 19, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

LTRN moved below its 50-day moving average on November 11, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LTRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for LTRN entered a downward trend on November 08, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LTRN advanced for three days, in of 210 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.196) is normal, around the industry mean (13.749). P/E Ratio (0.000) is within average values for comparable stocks, (88.241). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.798). LTRN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (221.024).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. LTRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LTRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
LTRN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1920 McKinney Avenue
Phone
+1 972 277-1136
Employees
21
Web
https://www.lanternpharma.com